Equillium (EQ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
The annual meeting will be held virtually on May 28, 2026, with voting available online, by phone, or by mail for shareholders of record as of April 1, 2026.
Four key proposals are up for vote: election of two Class II directors, approval of a reverse stock split, ratification of Crowe LLP as auditor, and an increase in authorized common shares.
The Board recommends voting in favor of all proposals and emphasizes the importance of shareholder participation for quorum.
Voting matters and shareholder proposals
Proposal 1: Elect two Class II directors (Charles McDermott and Bruce D. Steel) to serve until 2029.
Proposal 2: Approve a reverse stock split at a ratio between 1-for-2 and 1-for-20, at the Board's discretion, effective by December 31, 2027.
Proposal 3: Ratify Crowe LLP as independent auditor for fiscal year ending December 31, 2026.
Proposal 4: Approve an increase in authorized common shares from 200,000,000 to 400,000,000.
Shareholders may submit proposals for the 2027 annual meeting by specified deadlines.
Board of directors and corporate governance
The Board will reduce from seven to six members prior to the meeting.
Four directors are considered independent under Nasdaq rules; the Board is chaired by Daniel M. Bradbury.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all with independent members.
The Board regularly holds executive sessions and values diversity in skills and backgrounds.
Stockholders can communicate with the Board via a formal process.
Latest events from Equillium
- EQ504 targets UC with a novel, validated approach, backed by strong science and financial runway.EQ
Corporate presentation - Net loss narrowed, cash runway into 2029, and clinical programs advancing but more funding needed.EQ
Q2 2026 - EQ504, a novel AhR modulator for ulcerative colitis, enters Phase I in mid-2026 after $50M financing.EQ
Cantor Global Healthcare Conference 2025 - ABX464 and EQ504 modulate AhR to induce miR-124, reduce inflammation, and improve barrier function.EQ
Status update - EQ504 targets UC with a novel, colon-specific approach, aiming for improved remission and safety.EQ
Corporate presentation - Q1 2026 net loss narrowed, cash runway into 2029, Phase 1 EQ504 study set for mid-2026.EQ
Q1 2026 - Key votes include director elections, reverse split, share increase, and auditor ratification.EQ
Proxy filing - 18.9M shares registered for resale after $35M private placement; pipeline targets autoimmune diseases.EQ
Registration filing - Shareholders will vote on director elections, reverse stock split, auditor ratification, and share authorization.EQ
Proxy filing